OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Accordino on the Utility of CDK4/6 Inhibitors in HR+/HER2

February 6th 2020

Melissa K. Accordino, MD, MS, discusses the utility of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Dr. Usmani on Treatment Considerations in Relapsed/Refractory Multiple Myeloma

February 6th 2020

Saad Z. Usmani, MD, FACP, discusses treatment considerations in relapsed/refractory multiple myeloma.

Dr. Mims on Waiting for Molecular Tests Before Starting Therapy in AML

February 6th 2020

Alice S. Mims, MD, discusses her recommendations regarding holding therapy until molecular test results are received for symptomatic patients with acute myeloid leukemia.

Dr. Cusnir on the Role of Ramucirumab in Gastric Cancer

February 6th 2020

Mike Cusnir, MD, discusses the utilization of ramucirumab in gastric cancer.

Dr. Vaishampayan on the Shifting Role of Cytoreductive Nephrectomy in RCC

February 6th 2020

Ulka Vaishampayan, MD, discusses the shifting role of cytoreductive nephrectomy in renal cell carcinoma.

Dr. Putcha on Blood-Based Detection of Early-Stage CRC

February 6th 2020

Girish Putcha, MD, PhD, chief medical officer and clinical laboratory director, Freenome, discusses blood-based detection of early-stage colorectal cancer (CRC) using multiomics and machine learning.

Dr. Hamilton on the DESTINY-Breast01 Trial in HER2+ Breast Cancer

February 6th 2020

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the phase II DESTINY-Breast01 trial in advanced HER2-positive breast cancer.

Dr. Sartor on Emerging Agents in Prostate Cancer

February 6th 2020

A. Oliver Sartor, MD, professor of medicine, medical director, Tulane Cancer Center, and C. E. and Bernadine Laborde Professor of Cancer Research, Departments of Medicine and Urology, Tulane University, discusses emerging agents in prostate cancer.

Dr. Awan on the Role of Chemotherapy in CLL

February 5th 2020

Farrukh Awan, MD, discusses the role of chemotherapy in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Putcha on the Use of Blood-Based Screening Assays in CRC

February 5th 2020

Girish Putcha, MD, PhD, discusses the use of blood-based screening assays in colorectal cancer (CRC).

Dr. Voorhees on the Role of CAR T-Cell Therapy in Multiple Myeloma

February 5th 2020

Peter Voorhees, MD, discusses the role of CAR T-cell therapy in multiple myeloma.

Dr. Khan on Overall Incidence of Gastric Cancer and CRC

February 5th 2020

Amir Khan, MD, discusses trends in the overall incidence of gastric cancer and colorectal cancer.

The Search for Biomarkers in Metastatic Breast Cancer

February 5th 2020

James M. Reuben, PhD, MBA, discusses the search for biomarkers in patients with metastatic breast cancer.

Dr. Morris on Treatment Considerations for CRPC

February 5th 2020

David Morris, MD, FACS, discusses choosing the best agent to treat patients with nonmetastatic castration-resistant prostate cancer.

Dr. Olin on FLT3 Inhibitor Research in AML

February 5th 2020

Rebecca L. Olin, MD, MSCE, discusses research surrounding FLT3 inhibitors as a treatment for patients with acute myeloid leukemia.

Dr. Villa on the Efficacy of Induction Therapy With BR in MCL

February 5th 2020

Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, Department of Medicine, The University of British Columbia, discusses the efficacy of induction therapy with bendamustine plus rituximab (Rituxan) in mantle cell lymphoma (MCL).

Dr. Burris on Investigational Approaches in TNBC

February 5th 2020

Howard A. "Skip" Burris, III, MD, FASCO, FACP, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019-2020 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses investigational immunotherapy approaches in triple-negative breast cancer (TNBC).

Dr. Woyach on the Design of the Ongoing Alliance A041702 Trial in CLL

February 5th 2020

Jennifer Woyach, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses the design of the ongoing phase III Alliance A041702 trial in chronic lymphocytic leukemia (CLL).

Dr. Lawrenz on Patient Feedback of Preoperative 5-Fraction RT Sarcoma Study

February 4th 2020

Joshua M. Lawrenz, MD, discusses patient feedback of a study on preoperative 5-fraction radiation therapy for soft tissue sarcoma with immediate resection.

Dr. Crew on New Research in Advanced HER2+ Breast Cancer

February 4th 2020

Katherine Crew, MD, MS, discusses new research in the advanced HER2-positive breast cancer landscape.